Recro Pharma, Inc. REPH was a big mover last session, as its shares rose almost 20% on the day. The move came after the company announced positive phase 3 trial results for its acute postoperative pain treatment. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $6.92 to $8.71 in the past one-month time frame.
Over the last 30 days, the company witnessed one positive and two negative estimate revisions while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Recro Pharma currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the medical-drugs space is Sucampo Pharmaceuticals, Inc. SCMP, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research